Bayer's Roundup Reckoning Returns to Court as Refinancing and Ohio Expansion Roll On

Bayer stock fell 10% in a week as a new Monsanto Roundup trial opened in Missouri, even as the group placed EUR 2 billion in hybrid bonds.

A fresh legal front in the long-running Roundup saga has rattled Bayer shareholders, even as the Leverkusen-based group quietly strengthens its balance sheet and lays the groundwork for a major US manufacturing push. Over a seven-day stretch, the stock shed 10%, closing Friday at EUR 45.02.

The trigger was a civil trial that opened Tuesday in the US state of Missouri against Bayer subsidiary Monsanto. Three plaintiffs allege the company failed to adequately test Roundup before bringing it to market. That argument marks a departure from earlier litigation, which centered on the absence of cancer warnings on packaging. The Missouri case also sits outside the proposed collective settlement, and Bayer has rejected the claims.

A Legal Overhang That Refuses to Lift

Market participants had been hoping for a swift breakthrough in the sprawling US glyphosate litigation. Those expectations went unmet, and media reports pointed to persistent legal and regulatory risks in the United States rather than any single fresh catalyst behind Thursday's selling. The episode underscores how heavily North American courtroom battles continue to shape how investors value the company. Bayer has recovered from earlier lows during the year, yet bouts of legal uncertainty repeatedly drag the valuation back into more cautious territory.

Capital Structure Gets a Boost

While the litigation simmers, Bayer has been busy on the financing side. On 23 September the group placed hybrid bonds totaling EUR 2 billion, split across two tranches. Each carries a maturity of three decades, with the company gaining its first early redemption options after multi-year holding periods. The placement is aimed at securing the group's long-term financial footing.

Ohio Bet and Pipeline Progress

Strategic projects overseas are moving ahead regardless of the courtroom noise. Bayer plans a new pharmaceutical production site in New Albany, Ohio, backed by a USD 2.2 billion investment. Roughly 600 new jobs are expected to be created there, with operations scheduled to come on stream in stages from 2031.

Regulatory momentum in the development pipeline has accompanied that expansion. The US Food and Drug Administration granted the active ingredient Lynkuet an accelerated review for an additional indication, while development projects at subsidiary BlueRock Therapeutics picked up special designations in both the US and Europe.

There has been organizational change as well. Dr. Christoph Koenen took on the role of Chief Medical Officer of the pharmaceutical division alongside his existing duties, tasked with steering the segment's medical strategy. None of these operational moves resonated much on the trading floor, where caution over the legal situation dominates.

What Investors Watch Next

Attention now turns to the next set of business figures. Bayer will publish its quarterly statement for the third quarter of 2026 on 3 November 2026 at 07:30 CET, followed by an investor conference at 14:00 CET. Despite the recent consolidation, the stock is up 22% since the start of the year — a reminder that the legal question in the US remains the single biggest swing factor for the shares.